Importantly, this heterogeneity is not limited to the magnitude of weight loss, but may also include minimal treatment response, persistent appetite, weight regain, and, in rare cases, paradoxical increases in appetite and food intake
Patients with the following conditions should avoid FDA-approved semaglutide products: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Severe allergic reactions to semaglutide History of pancreatitis Diabetic retinopathy Kidney problems Serious stomach issues Pregnancy or breastfeeding Compounded semaglutide , lacking FDA approval, does not have the same established safety guidelines or defined patient populations
Take care of your physical health
If you click a merchant link and buy a product or service on their website, we may be paid a fee by the merchant
Usually kills the sweet tooth, that works quite well